In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTX), with a price target of $20. The company’s shares opened today at $7.34.
White wrote:
“Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 45% POS for umbralisib in 40% POS for ublituximab in MS.”
According to TipRanks.com, White is a 5-star analyst with an average return of 16.6% and a 49.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.
TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.65 and a one-year low of $3.32. Currently, TG Therapeutics has an average volume of 1.93M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib.
